Figure 2. Minipump delivery of bretazenil into the 4^th ventricle is more efficacious than delivery into the 3^rd ventricle.

(A) Percentage of initial body weight of DT-treated, Agrp^DTR/+ mice in which bretazenil (75 ng/hr; 1/10^th of the dosage used in Figure 1) or vehicle was chronically administered either subcutaneously (sc) or directly into the 3^rd (3v) or 4^th (4v) ventricle.

(B) Percentage of initial body weight of DT-treated, Agrp^DTR/+ mice in which bretazenil (15 ng/hr; 1/50^th of the dosage used in Figure 1) or vehicle was chronically administered directly into the 3^rd or 4^th ventricle. Note that abrupt withdrawal of bretazenil delivered into the 4^th ventricle at Day 4 resulted in more profound decline of body weight than that was shown by the AgRP-ablated mice infused with vehicle; *, p < 0.01, ANOVA.

(C) Percentage of initial body weight of DT-treated, Agrp^DTR/+ mice in which bretazenil (7.5 or 2.5 ng/hr, 1/100^th or 1/300^th of the dosage used in Figure 1, respectively) or vehicle was chronically administered directly into either the 3^rd or 4^th ventricle.

N = 6 - 8 for each group. Error bars represent the SEM.